

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
103951Orig1s5173

**CLINICAL PHARMACOLOGY AND
BIOPHARMACEUTICS REVIEW(S)**

Clinical Pharmacology Review

BLA Number:	STN 103951/5173	Submission Date: 12/26/07
Product Name:	Aranesp (Darbepoetin)	
Route of Administration:	Subcutaneous (s.c.) injection	
Proposed Indication:	Anemia	
Submission Type:	SLR	
Sponsor:	Amgen	
Reviewer:	Aakanksha Khandelwal, Ph.D.	
Team Leader:	Hong Zhao, Ph.D.	

Introduction


The purpose of this submission is to convert the original labeling for Aranesp® (darbepoetin) to the new PLR (Physicians Labeling Rule) format.

Summary of darbepoetin label changes:


Original version of label provided by the sponsor with FDA recommended changes:

2 pages of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

We recommend that the sponsor use median values instead of mean values when discussing half-life and peak concentrations due to the large range in values.

 10/20/08

Aakanksha Khandelwal, Ph.D.
Reviewer
CDER/OTS/OCP/DCP5

 10/20/08

Hong Zhao, Ph.D.
Team Leader
CDER/OTS/OCP/DCP5

**Office of Clinical Pharmacology
NDA/BLA Filing and Review Form**

General Information About the Submission

	Information		Information
BLA Number	STN 103951/5173, (b) (4)	Brand Name	Aranesp
OCP Division	DCP 5	Generic Name	Darbepoetin alfa
Medical Division	DBOP	Drug Class	Biologics
OCP Reviewer	Hong Zhao	Indication(s)	Anemia
OCP Team Leader/Division Director	Hong Zhao / Atik Rahman	Dosage Form	Injection solution
		Dosing Regimen	Weekly, Biweekly
Date of Submission	12/20/2008	Route of Administration	IV, SC
Estimated Due Date of OCP Review	8/28/2008	Sponsor	Amgen
PDUFA Due Date	10/28/2008	Priority Classification	S
Division Due Date	8/28/2008		

Clin. Pharm. Information

	"X" if included at filing	Number of studies submitted	Number of studies reviewed	Critical Comments If any
STUDY TYPE				
Table of Contents present and sufficient to locate reports, tables, data, etc.	x	9		Only a few studies had PK data collected
Tabular Listing of All Human Studies	x			
HPK Summary	x			
Labeling	x			
Reference Bioanalytical and Analytical Methods				
I. Clinical Pharmacology				
Mass balance:				
Isozyme characterization:				
Blood/plasma ratio:				
Plasma protein binding:				
Pharmacokinetics (e.g., Phase I) -				
<i>Healthy Volunteers-</i>				
single dose:				
multiple dose:				
<i>Patients-</i>				
single dose:				
multiple dose:	x			
Dose proportionality -	x			
fasting / non-fasting single dose:				
fasting / non-fasting multiple dose:				
Drug-drug interaction studies -				
In-vivo effects on primary drug:				
In-vivo effects of primary drug:				
In-vitro:				
Subpopulation studies -				
ethnicity:				
gender:				
pediatrics:				
geriatrics:				
renal impairment:				

PD:				
Phase 2:	x			
Phase 3:	x			
PK/PD:				
Phase 1 and/or 2, proof of concept:	x			
Phase 3 clinical trial:	x			
Population Analyses -				
Data rich:				
Data sparse:	x			
II. Biopharmaceutics				
Absolute bioavailability:				
Relative bioavailability -				
solution as reference:				
alternate formulation as reference:				
Bioequivalence studies -				
traditional design; single / multi dose:				
replicate design; single / multi dose:				
Food-drug interaction studies:				
In-Vitro Release BE				
(IVIVC):				
Bio-wavier request based on BCS				
BCS class				
III. Other CPB Studies				
Genotype/phenotype studies:				
Chronopharmacokinetics				
Pediatric development plan				
Literature References	x			
Total Number of Studies	9			
Filability and QBR comments				
	"X" if yes	Comments		
Application filable?	x			
Comments sent to firm?	none			
QBR questions (key issues to be considered)	<ol style="list-style-type: none"> 1. What are the PK characteristics of Darbepoetin alfa observed over the 12 weeks of dosing in Study NESP980291? 2. What is the dose-response relationship between doses of 4.5 and ¹²mcg/kg for the hemoglobin response and mean change in hemoglobin endpoints? 3. What is the incidence of immunogenicity of Aranesp? 4. What is the risk-benefit ratio for using ESAs in Small-Cell Lung Cancer (SCLC) patient population and in populations with other cancer types? 			
Other comments or information not included above	none			
Primary reviewer Signature and Date	Zhao, Hong	<i>Hong Zhao</i> 2/15/08		
Secondary reviewer Signature and Date	Nam Atiqur Rahman	<i>Atiqur Rah</i> 2/15/08		

CC: NDA/BLAXXX, HFD-850(Electronic Entry or Lee), HFD-107(CSO), HFD-860(TL, DD, DDD), CDR (B. Murphy)

OFFICE OF CLINICAL PHARMACOLOGY REVIEW

BLA	STN 103951/5173/309
Submission Date(s)	October 23, 2009
PDUFA Due Date	April 27, 2010
Brand Name	Aranesp®
Generic Name	Darbepoetin alfa
Reviewer	Aakanksha Khandelwal, Ph.D.
Team Leader	Hong Zhao, Ph.D.
OCP Division	DCP 5
OND Division	OODP/DBOP
Sponsor	Amgen
Submission Type	Labeling supplement (PLR Conversion- Resubmission)

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY	2
1.1. Recommendations.....	2
2. DETAILED LABELING RECOMMENDATIONS	3
2.1. Sponsor Proposed Labeling Changes and FDA Revisions.....	3

1. EXECUTIVE SUMMARY

Aranesp[®] (darbepoetin alfa) was approved by the FDA on September 17, 2001 for the treatment of anemia associated with chronic renal failure including both patients on dialysis and those not on dialysis.

In this labeling resubmission, the sponsor is proposing to convert the Aranesp[®] label to PLR (Physician's Labeling Rule) format. There is no new data or new studies included in this submission from a clinical pharmacology standpoint. The Clinical Pharmacology related changes are made to the following sections:

- Sections: 7 Drug Interactions updated to reflect standard labeling language
- 12.3 Pharmacokinetics has been updated to enhance clarity

See FDA recommended modifications below.

1.1 Recommendations

The application is acceptable from a clinical pharmacology perspective provided that the applicant agrees to the labeling recommendations.

 2/4/10

Aakanksha Khandelwal, Ph.D.
Reviewer
CDER/OTS/OCP/DCP5

 2-4-10

Hong Zhao, Ph.D.
Team Leader
CDER/OTS/OCP/DCP5

2. DETALIED LABELING RECOMMENDATIONS

2.1 Sponsor Proposed Labeling Changes and FDA Revisions

FDA recommended changes are made to the following sections of the label as shown below.

1 page of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

